HK18496A - Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) - Google Patents

Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) Download PDF

Info

Publication number
HK18496A
HK18496A HK18496A HK18496A HK18496A HK 18496 A HK18496 A HK 18496A HK 18496 A HK18496 A HK 18496A HK 18496 A HK18496 A HK 18496A HK 18496 A HK18496 A HK 18496A
Authority
HK
Hong Kong
Prior art keywords
aminothiazol
cephem
vinyl
solution
carboxylic acid
Prior art date
Application number
HK18496A
Other languages
English (en)
French (fr)
Inventor
Takaya Takao
Shirai Fumiyuki
Nakamura Hitoshi
Inaba Yasunobu
Original Assignee
安斯泰来制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16519432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK18496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 安斯泰来制药有限公司 filed Critical 安斯泰来制药有限公司
Publication of HK18496A publication Critical patent/HK18496A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

  1. Verfahren zur Herstellung von kristalliner 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer), die in ihrem Pulver-Röntgenbeugungsdiagramm Peaks aufweist bei den verschiedenen Beugungswinkeln, wie sie in der folgenden Tabelle angegeben sind, wobei die Meßbedingungen die folgenden waren: Target: Cu   Filter: Ni Spannung 30 kV   Strom: 10 mA Detektor: Szintillations-Zähler das umfaßt das Auflösen der 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer) in einem Alkohol, das weitere langsame Rühren der Lösung unter Erwärmen, das anschließende Abkühlen der Lösung auf Raumtemperatur und das Stehenlassen der Lösung.
  2. Verfahren zur Herstellung der kristallinen 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer), das umfaßt das Auflösen der 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer) in einem Alkohol, das weitere langsame Rühren der Lösung unter Erwärmen, das anschließende Abkühlen der Lösung auf Raumtemperatur und das Stehenlassen der Lösung.
  3. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, das umfaßt das Mischen der kristallinen Verbindung nach einem der Ansprüche 1 bis 2 als aktiven Bestandteil (Wirkstoff) mit einem pharmazeutisch akzeptablen, im wesentlichen nicht-toxischen Träger oder Exzipienten.
  4. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die kristalline 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer) enthält, das umfaßt das Auflösen der 7-[2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carbonsäure (syn-Isomer) in einem Alkohol, das weitere langsame Rühren der Lösung unter Erwärmen, das anschließende Abkühlen der Lösung auf Raumtemperatur und das Stehenlassen der Lösung sowie das Mischen derselben als aktiven Bestandteil (Wirkstoff) mit einem pharmazeutisch akzeptablen, im wesentlichen nicht-toxischen Träger oder Exzipienten.
  5. Verfahren zur Verwendung der Verbindung nach einem der Ansprüche 1 bis 2 zur Herstellung eines Arzneimittels zur Behandlung oder Prävention von Infektionserkrankungen.
HK18496A 1987-08-19 1996-02-01 Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) HK18496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20619987 1987-08-19

Publications (1)

Publication Number Publication Date
HK18496A true HK18496A (en) 1996-02-09

Family

ID=16519432

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18496A HK18496A (en) 1987-08-19 1996-02-01 Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)

Country Status (11)

Country Link
US (1) US4935507A (de)
EP (1) EP0304019B1 (de)
KR (1) KR970008126B1 (de)
AT (1) ATE123221T1 (de)
AU (1) AU617347B2 (de)
CA (1) CA1297096C (de)
DE (1) DE3853901T2 (de)
ES (1) ES2072856T3 (de)
HK (1) HK18496A (de)
IE (1) IE67348B1 (de)
ZA (1) ZA885709B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405283B (de) * 1997-04-04 1999-06-25 Biochemie Gmbh Neues kristallines 7-(z)-(2-(2-aminothiazol-4-yl) -2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carbonsäure dicyclohexylammoniumsalz und verfahren zu dessen herstellung
US6888124B1 (en) 1999-03-24 2005-05-03 Shell Oil Company Method to monitor internal parameters of electrical motor systems
WO2002083634A2 (en) * 2001-04-17 2002-10-24 Ranbaxy Laboratories Limited Process for the preparation of cefpodoxime acid
KR100451672B1 (ko) 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
KR20030018536A (ko) * 2001-08-30 2003-03-06 임득수 유리제품의 표면처리방법
AU2002347539A1 (en) * 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
US7297800B2 (en) * 2001-12-27 2007-11-20 Ajinomoto Co., Inc. Process of producing glutamate derivatives
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
ITMI20020913A0 (it) * 2002-04-29 2002-04-29 Acs Dobfar Spa Nuova forma cristallina del cefdinir
US6800756B2 (en) * 2002-05-03 2004-10-05 Orchid Chemicals And Pharmaceuticals, Ltd. Method for the preparation of ceftiofur sodium and its intermediates
ATE501154T1 (de) * 2002-08-13 2011-03-15 Sandoz Ag Ein cefdinir-zwischenprodukt
RU2307871C2 (ru) 2002-08-26 2007-10-10 Адзиномото Ко., Инк. НОВАЯ АЛЬДОЛАЗА И СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ α-КЕТОКИСЛОТ
WO2004046154A1 (en) * 2002-11-15 2004-06-03 Orchid Chemicals & Pharmaceuticals Ltd Novel amorphous hydrate of a cephalosporin antibiotic
AU2003289264A1 (en) 2002-12-09 2004-06-30 Ajinomoto Co., Inc. Mutant d-aminotransferase and process for producing optically active glutamic acid derivative using the same
ITMI20022724A1 (it) * 2002-12-20 2004-06-21 Antibioticos Spa Sali cristallini del cefdinir.
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
EP1609793A4 (de) * 2003-03-24 2008-06-25 Sandoz Ag Neuer kristall von 7-¬2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido-3-vinyl-3-cephem-4-carbonsäure(syn-isomer) und verfahren zu dessen herstellung
WO2004104010A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Crystalline form of cefdinir
US20040242556A1 (en) * 2003-06-02 2004-12-02 Ramesh Dandala Novel crystalline form of cefdinir
US20050137182A1 (en) * 2003-06-02 2005-06-23 Ramesh Dandala Novel crystalline form of cefdinir
US7098329B2 (en) * 2003-06-19 2006-08-29 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a cephalosporin antibiotic
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
US20050059819A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Cefdinir pyridine salt
US20050113355A1 (en) * 2003-09-12 2005-05-26 Duerst Richard W. Cefdinir pyridine salt
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
WO2006018807A1 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Crystalline forms of cefdinir
WO2006059753A1 (en) * 2004-11-30 2006-06-08 Astellas Pharma Inc. Novel oral pharmaceutical suspension of cefdinir crystal
GB2421024A (en) * 2004-12-07 2006-06-14 Sandoz Ag Cefdinir crystalline form C
WO2006117794A1 (en) * 2005-05-02 2006-11-09 Hetero Drugs Limited A novel crystalline form of cefdinir
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR100912214B1 (ko) * 2005-10-31 2009-08-14 테바 파마슈티컬 인더스트리즈 리미티드 세프디니르 세슘 염의 결정형
WO2007053723A2 (en) * 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Process for the preparation of cefdinir
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
ITMI20071628A1 (it) 2007-08-06 2007-11-05 Acs Dobfar Spa Sintesi di 3-alchenilcefalosporine e nuovi intermedi utili ad esse correlati
CN101481383B (zh) * 2008-12-31 2012-01-11 杭州奥默医药技术有限公司 头孢地尼酸式复盐化合物及制备方法
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
MX352760B (es) 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
CN102643293A (zh) * 2012-03-30 2012-08-22 石药集团中诺药业（石家庄）有限公司 头孢地尼三元复合物及其用于制备头孢地尼的方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN103012433B (zh) * 2012-12-13 2015-06-24 珠海保税区丽珠合成制药有限公司 头孢地尼晶型b的制备方法
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
EP3043797B1 (de) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Behandlung von infektionen mit ceftolozan/tazobactam bei personen mit beeinträchtigter nierenfunktion
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN103622933B (zh) * 2013-12-19 2015-04-08 石家庄市华新药业有限责任公司 一种头孢地尼胶囊及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8323034D0 (en) * 1983-08-26 1983-09-28 Fujisawo Pharmaceutical Co Ltd 7-substituted-3-vinyl-3-cephem compounds

Also Published As

Publication number Publication date
ZA885709B (en) 1989-04-26
DE3853901D1 (de) 1995-07-06
EP0304019A3 (en) 1990-12-27
ATE123221T1 (de) 1995-06-15
AU2099888A (en) 1989-02-23
IE882411L (en) 1989-02-19
IE67348B1 (en) 1996-03-20
DE3853901T2 (de) 1995-10-12
AU617347B2 (en) 1991-11-28
ES2072856T3 (es) 1995-08-01
US4935507A (en) 1990-06-19
KR970008126B1 (ko) 1997-05-21
EP0304019B1 (de) 1995-05-31
CA1297096C (en) 1992-03-10
EP0304019A2 (de) 1989-02-22
KR890003778A (ko) 1989-04-18

Similar Documents

Publication Publication Date Title
EP0304019B1 (de) Kristalline 7-(2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxyl-Säure (syn Isomer)
EP0780390A1 (de) Kristallmodifikation des CDCH, Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
KR102222443B1 (ko) 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민의 신규염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DK170070B1 (da) Krystallinsk monohydrat af et beta-lactam-antibiotikum, fremgangsmåde til fremstilling heraf og farmaceutisk præparat indeholdende monohydratet
EP0440642B1 (de) Rifapentin-hydrohalide
EP0464927B1 (de) 3-[(5-Methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo[4,5-b]-pyridin-2-amin-2-hydroxy-1,2,3-propantricarboxylat
JP3793583B2 (ja) 抗菌性化合物の結晶
US9593116B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
EP0944612B1 (de) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamidhydrat
FI62311C (fi) Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat
KR100756471B1 (ko) 8-시아노-1-사이클로프로필-7-(1ｓ,6ｓ-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 ｃ
SK1572004A3 (sk) Bezvodé kryštalické formy gabapentinu
CS195746B2 (en) Process for preparing crystalline methanolate of natrium salt of cephamandole
EP3004103A1 (de) Kristalline form von n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-carboxamid zur behandlung myeloproliferativen erkrankungen
KR100740947B1 (ko) 8-시아노-1-사이클로프로필-7-(1ｓ,6ｓ-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 ａ
KR100756474B1 (ko) 8-시아노-1-사이클로프로필-7-(1ｓ,6ｓ-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 ｄ
EP1413578A1 (de) Neuer kristall eines arylethensulfonamidderivats und verfahren zu dessen herstellung
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
WO2014193865A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
IE903817A1 (en) Anhydrous crystal of 4-carbamoyl-1-ß-d-ribofuranosyl imidazolium-5-olate
WO2014193881A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
KR20230004723A (ko) 프탈라지논 화합물의 결정형
FI82457B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar kristallform çaçav 1-benzhydyl-4 -allylpiperazindihydroklorid.
JPH03500781A (ja) 結晶（５ｒ，６ｓ）‐２‐カルバモイルオキシメチル‐６‐［（１ｒ）‐ヒドロキシエチル］‐２‐ペネム‐カルボン酸及びその医薬処方物
HK40090484A (zh) 八氢噻吩并喹啉化合物的琥珀酸盐及其晶体

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080816